BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130:2245-57. [PMID: 17337484 DOI: 10.1093/brain/awm004] [Cited by in Crossref: 291] [Cited by in F6Publishing: 310] [Article Influence: 18.2] [Reference Citation Analysis]
Number Citing Articles
1 Fujii K, Shiohama T, Uchida T, Ikehara H, Fukuhara T, Sawada D, Aoyama H, Uchikawa H, Yoshii S, Arahata Y, Shimojo N, Misawa S, Kuwabara S. Nationwide survey of childhood Guillain-Barré syndrome, Fisher syndrome, and Bickerstaff brainstem encephalitis in Japan. Brain and Development 2023;45:16-25. [DOI: 10.1016/j.braindev.2022.09.007] [Reference Citation Analysis]
2 Martinelli-Boneschi F, Colombo A, Bresolin N, Sessa M, Bassi P, Grampa G, Magni E, Versino M, Ferrarese C, Zarcone D, Albanese A, Micieli G, Zanferrari C, Cagnana A, Ferrante C, Zilioli A, Locatelli D, Calloni MV, Delodovici ML, Pozzato M, Patisso V, Bortolan F, Foresti C, Frigeni B, Canella S, Xhani R, Crabbio M, Clemenzi A, Mauri M, Beretta S, La Spina I, Bernasconi S, De Santis T, Cavallini A, Ranieri M, D'Adda E, Fruguglietti ME, Peverelli L, Agosti E, Leoni O, Rigamonti A, Salmaggi A. COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy). Neurol Sci 2023;44:437-46. [PMID: 36289117 DOI: 10.1007/s10072-022-06429-6] [Reference Citation Analysis]
3 Reyes-Niño S, Rodríguez-Orozco JE, Moutran-Barroso HG, Kreinter-Rosembaun H, Gaviria-Carrillo M, Salej-Durán V, Mancera-Charry J, Villegas AC, Cuellar-Giraldo D, Torres-Sandoval JS, Gómez-Mazuera Á, Duque-Samper A, Toro-Gómez J. Controversies in neuroimmunology: multiple sclerosis, vaccination, SARS-CoV-2 and other dilemas. Biomedica 2022;42:78-99. [PMID: 36322548 DOI: 10.7705/biomedica.6366] [Reference Citation Analysis]
4 Tu WC, Chang ST, Huang CH, Cheng YY, Hsu CS. Guillain-Barré Syndrome with Respiratory Failure following Spine Surgery for Incomplete Cervical Cord Injury: A Case Report and Literature Review. Medicina (Kaunas) 2022;58:1063. [PMID: 36013530 DOI: 10.3390/medicina58081063] [Reference Citation Analysis]
5 Sivadasan A, Bril V. Therapies in Autoimmune Peripheral Neuropathies beyond Intravenous Immunoglobulin, Plasma Exchange and Corticosteroids: An Analytical Review. Transfusion Medicine Reviews 2022. [DOI: 10.1016/j.tmrv.2022.05.002] [Reference Citation Analysis]
6 Fokkink WJR, van Tilburg SJ, de Winter BCM, Sassen SDT, van Doorn PA, Koch BCP, Jacobs BC. Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome. Clin Pharmacokinet 2022. [PMID: 35781631 DOI: 10.1007/s40262-022-01136-z] [Reference Citation Analysis]
7 Mao M, Fan W, Zheng Y, Qi P, Xi M, Yao Y. Upregulation of N-Type Voltage-Gated Calcium Channels Induces Neuropathic Pain in Experimental Autoimmune Neuritis. Evid Based Complement Alternat Med 2022;2022:8547095. [PMID: 35754699 DOI: 10.1155/2022/8547095] [Reference Citation Analysis]
8 Covino M, Romozzi M, Simeoni B, Di Paolantonio A, Sabatelli M, Franceschi F, Luigetti M. Guillain-Barré syndrome from an emergency department view: how to better predict the outcome? Neurol Res 2022;:1-5. [PMID: 35580194 DOI: 10.1080/01616412.2022.2075661] [Reference Citation Analysis]
9 Nikolaus M, Kühne F, Tietze A, Thumfart J, Kempf C, Gratopp A, Knierim E, Bittigau P, Kaindl AM. Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders. J Child Neurol 2022;37:505-16. [PMID: 35435761 DOI: 10.1177/08830738221089476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shah N, Shrivastava M, Kumar S, Nagi RS. Supervised, individualised exercise reduces fatigue and improves strength and quality of life more than unsupervised home exercise in people with chronic Guillain-Barré syndrome: a randomised trial. J Physiother 2022:S1836-9553(22)00015-7. [PMID: 35396175 DOI: 10.1016/j.jphys.2022.03.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kenan G, Regev T, Kushnir M, Cohen O, Gandelman-marton R, Kimiagar I, Armon C. Reasons for delayed treatment initiation in Guillain-Barre syndrome. Journal of the Neurological Sciences 2022;434:120179. [DOI: 10.1016/j.jns.2022.120179] [Reference Citation Analysis]
12 Islam B, Islam Z, Endtz HP, Jahan I, Jacobs BC, Mohammad QD, Franssen H. Electrophysiology of Guillain-Barré syndrome in Bangladesh: A prospective study of 312 patients. Clin Neurophysiol Pract 2021;6:155-63. [PMID: 35112034 DOI: 10.1016/j.cnp.2021.03.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Aly AS, Alkolfat F, Mansour ER, Salama S. Guillain-Barre syndrome following COVID-19 vaccination: a case report and an updated review. Neuroimmunology Reports 2022;2:100083. [DOI: 10.1016/j.nerep.2022.100083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mitchell CW, Bertorini TE. Principles and Guidelines of Immunotherapy in Neuromuscular Disorders. Neuromuscular Disorders 2022. [DOI: 10.1016/b978-0-323-71317-7.00007-x] [Reference Citation Analysis]
15 El-abassi RN, Soliman M, Levy MH, England JD. Treatment and Management of Autoimmune Neuropathies. Neuromuscular Disorders 2022. [DOI: 10.1016/b978-0-323-71317-7.00015-9] [Reference Citation Analysis]
16 Rabinstein AA. Emergencies in Peripheral Neuropathies. Emergencies in Neuromuscular Disorders 2022. [DOI: 10.1007/978-3-030-91932-0_7] [Reference Citation Analysis]
17 Chakraborty D, Bhaumik S, Dey S, Chatterjee S. Uncommon course of a common disease: An interesting case of guillain–Barre syndrome. J Prim Care Spec 2022;0:0. [DOI: 10.4103/jopcs.jopcs_14_22] [Reference Citation Analysis]
18 Mosora O, Barcutean L, Balasa R, Fodor R, Maier S, Bajko Z, Stoian A, Motataianu A. Severe Acute Motor Axonal Neuropathy associated with Influenza-A (H1N1) Infection and Prolonged Respiratory Failure - A Case Report. J Crit Care Med (Targu Mures) 2021;7:302-7. [PMID: 34934821 DOI: 10.2478/jccm-2021-0030] [Reference Citation Analysis]
19 Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. Clin Med Insights Oncol 2021;15:11795549211056261. [PMID: 34866959 DOI: 10.1177/11795549211056261] [Reference Citation Analysis]
20 Gu BM, Ko HH, Lee HK, Ra YJ, Lee HS, Kim HS. Guillain-Barré Syndrome after Lung Transplantation in the Immediate Postoperative Period: Case Report. J Chest Surg 2021;54:396-9. [PMID: 33767020 DOI: 10.5090/jcs.20.074] [Reference Citation Analysis]
21 Verboon C, Harbo T, Cornblath DR, Hughes RAC, van Doorn PA, Lunn MP, Gorson KC, Barroso F, Kuwabara S, Galassi G, Lehmann HC, Kusunoki S, Reisin RC, Binda D, Cavaletti G, Jacobs BC; IGOS consortium, GOS consortium. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. J Neurol Neurosurg Psychiatry 2021;92:1080-8. [PMID: 34103340 DOI: 10.1136/jnnp-2020-325815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Siriwardena AN, Akanuwe JNA, Botan V, Laparidou D, Curtis F, Jackson J, Asghar ZB, Hodgson TL. Patient-reported symptoms and experience following Guillain-Barré syndrome and related conditions: Questionnaire development and validation. Health Expect 2021. [PMID: 34597442 DOI: 10.1111/hex.13367] [Reference Citation Analysis]
23 Won S, Kim H, Kim J, Ryu J, Jung E, Yoo H, Seol I, Kim Y. A Case Report of a Patient with Guillain-Barre Syndrome Complaining of Limb Weakness and Facial Paralysis That Improved After Korean Medicine Treatment. J Int Korean Med 2021;42:695-706. [DOI: 10.22246/jikm.2021.42.4.695] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, Zimprich F. Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades. Sci Rep 2021;11:19170. [PMID: 34580356 DOI: 10.1038/s41598-021-98501-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sullivan BN, Fischer T. Age-Associated Neurological Complications of COVID-19: A Systematic Review and Meta-Analysis. Front Aging Neurosci 2021;13:653694. [PMID: 34408638 DOI: 10.3389/fnagi.2021.653694] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
26 Liu H, Yang L, Li Z, Cheng G. Fulminant Guillain-Barré syndrome developed after surgical treatment of intracranial hemorrhage due to arteriovenous malformation: a case report. Neurol Sci 2021. [PMID: 34324122 DOI: 10.1007/s10072-021-05384-y] [Reference Citation Analysis]
27 Bv S, S S, Rao S. Guillain - Barre syndrome following snake bite? An under-reported entity. IJN 2021;7:181-183. [DOI: 10.18231/j.ijn.2021.031] [Reference Citation Analysis]
28 Kakehi E, Kawakami T, Ishikawa Y, Matsuoka T, Nakagawa N, Morishita T, Taniguchi S, Akamatsu Y, Sakurai S, Hirotani A, Nozaki T, Shoji K, Adachi S, Kotani K, Matsumura M. Development of Acute Inflammatory Demyelinating Polyneuropathy 11 Days after Spinal Surgery: A Case Report and Literature Review. Case Rep Med 2021;2021:6283076. [PMID: 34367291 DOI: 10.1155/2021/6283076] [Reference Citation Analysis]
29 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 45.5] [Reference Citation Analysis]
30 Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M, Dhawan V, Pastores SM, Gutierrez C. Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. J Crit Care 2021;65:126-32. [PMID: 34139658 DOI: 10.1016/j.jcrc.2021.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Orlikowski D. Syndrome de Guillain-Barré. Pratique Neurologique - FMC 2021;12:109-115. [DOI: 10.1016/j.praneu.2021.03.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Cai L, Hu Z, Liao J, Hong S, Kong L, Chen L, Luo Y, Li T, Jiang L. Clinical Characterization of Anti-GQ1b Antibody Syndrome in Childhood. Front Pediatr 2021;9:649053. [PMID: 33996691 DOI: 10.3389/fped.2021.649053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Shang P, Feng J, Wu W, Zhang HL. Intensive Care and Treatment of Severe Guillain-Barré Syndrome. Front Pharmacol 2021;12:608130. [PMID: 33995011 DOI: 10.3389/fphar.2021.608130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
34 Al Maawali SM, Al Shibani AY, Nadeem AS, Al-Salti AM. Guillain-Barre syndrome: demographics, clinical features, and outcome in a single tertiary care hospital, Oman. Neurosciences (Riyadh) 2020;25:369-74. [PMID: 33459285 DOI: 10.17712/nsj.2020.5.20200057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Kwan J, Biliciler S. Guillain-Barré Syndrome and Other Acute Polyneuropathies. Clin Geriatr Med 2021;37:313-26. [PMID: 33858613 DOI: 10.1016/j.cger.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, Van Doorn PA, Dourado ME, Hughes RA, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Diretrizes Baseadas em Evidências Diagnóstico e manejo da Síndrome de Guillain–Barré em dez etapas. Rev Neurocienc 2021;29:1-52. [DOI: 10.34024/rnc.2021.v29.11725] [Reference Citation Analysis]
37 Raahimi MM, Kane A, Moore CE, Alareed AW. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'? BMJ Case Rep 2021;14:e240178. [PMID: 33462068 DOI: 10.1136/bcr-2020-240178] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
38 Chen J, Ma JX, Zuo CH, Zhang Q, Chen HT, Ma XL. Severe Guillain-Barré syndrome after surgery for multiple fractures: a rare case report with a 5-year follow-up and a brief review of the literature. BMC Musculoskelet Disord 2021;22:8. [PMID: 33397348 DOI: 10.1186/s12891-020-03864-4] [Reference Citation Analysis]
39 Craig A. Neuropathies. Braddom's Physical Medicine and Rehabilitation 2021. [DOI: 10.1016/b978-0-323-62539-5.00041-2] [Reference Citation Analysis]
40 Kesici S, Bayrakci B. Severe Guillain-Barré syndrome. Zika Virus Impact, Diagnosis, Control, and Models 2021. [DOI: 10.1016/b978-0-12-820267-8.00011-x] [Reference Citation Analysis]
41 Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol 2021;17:285-96. [PMID: 33649531 DOI: 10.1038/s41582-021-00467-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
42 Rhee SY, Jeon H, Kim SW, Lee JS. The effect of an end-effector type of robot-assisted gait training on patients with Guillain-Barre syndrome: a cross-sectional study. F1000Res 2020;9:1465. [DOI: 10.12688/f1000research.26246.1] [Reference Citation Analysis]
43 Ipe TS, Meyer EK, Sanford KW, Joshi SK, Wong ECC, Raval JS. Use of therapeutic plasma exchange for pediatric neurological diseases. J Clin Apher 2021;36:161-76. [PMID: 33063869 DOI: 10.1002/jca.21850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Korinthenberg R, Sejvar JJ. The Brighton Collaboration case definition: Comparison in a retrospective and prospective cohort of children with Guillain-Barré syndrome. J Peripher Nerv Syst 2020;25:344-9. [PMID: 32869396 DOI: 10.1111/jns.12411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Blackburn KM, Wang C. Post-infectious neurological disorders. Ther Adv Neurol Disord 2020;13:1756286420952901. [PMID: 32944082 DOI: 10.1177/1756286420952901] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
46 Peixoto HM, Romero GAS, de Araújo WN, de Oliveira MRF. Guillain-Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study. Trans R Soc Trop Med Hyg 2019;113:252-8. [PMID: 30892628 DOI: 10.1093/trstmh/trz010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
47 Qin Z, Gonsalvez DG, Wood RJ, Daemi F, Yoo S, Ivanusic JJ, Coulson EJ, Murray SS, Xiao J. Partial deletion of p75NTR in large-diameter DRG neurons exerts no influence upon the survival of peripheral sensory neurons in vivo. J Neurosci Res 2020;98:1987-98. [PMID: 32585763 DOI: 10.1002/jnr.24665] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Stribling JC, Robbins MS, Derosa AP. Mapping the Literature of Guillain–Barre Syndrome to Support Current Awareness among Neurologists. Journal of Hospital Librarianship 2020;20:111-119. [DOI: 10.1080/15323269.2020.1738839] [Reference Citation Analysis]
49 Gowan JM, Golla A, Liu A. Guillain‐Barré syndrome in a man presenting with upper extremity monoplegia. Clin Case Rep 2020;8:593-597. [DOI: 10.1002/ccr3.2613] [Reference Citation Analysis]
50 Altmann P, De Simoni D, Kaider A, Ludwig B, Rath J, Leutmezer F, Zimprich F, Hoeftberger R, Lunn MP, Heslegrave A, Berger T, Zetterberg H, Rommer PS. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J Neuroinflammation 2020;17:86. [PMID: 32183837 DOI: 10.1186/s12974-020-01737-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
51 López Ruiz R, Dotor García-soto J, Eichau S. Guillain-Barré syndrome after viral hepatitis A. Medicina Clínica (English Edition) 2020;154:238-239. [DOI: 10.1016/j.medcle.2019.02.043] [Reference Citation Analysis]
52 López Ruiz R, Dotor García-soto J, Eichau S. Síndrome de Guillain-Barré tras infección por el virus de la hepatitis A. Medicina Clínica 2020;154:238-239. [DOI: 10.1016/j.medcli.2019.02.005] [Reference Citation Analysis]
53 Liu Y, Liu S, Pan S, Gong Q, Yao J, Lu Z. The dynamic expression of canonical Wnt/β-catenin signalling pathway in the pathologic process of experimental autoimmune neuritis. Int J Neurosci 2020;130:1109-17. [PMID: 32009498 DOI: 10.1080/00207454.2020.1725511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Jia L, Zhang HL. Plasma Exchange-Intravenous Immunoglobulin Synergy in the Treatment of Guillain-Barré Syndrome. J Child Neurol 2020;35:346-7. [PMID: 32008481 DOI: 10.1177/0883073819900846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Le Guennec L. Manifestazioni neurologiche delle infezioni. EMC - Neurologia 2020;20:1-14. [DOI: 10.1016/s1634-7072(20)43298-2] [Reference Citation Analysis]
56 Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2020;1:CD008630. [PMID: 31981368 DOI: 10.1002/14651858.CD008630.pub5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Di Stefano V, Barbone F, Ferrante C, Telese R, Vitale M, Onofrj M, Di Muzio A. Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives. Eur J Inflamm 2020;18:205873922094234. [DOI: 10.1177/2058739220942340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 van Doorn PA. Guillain-Barré syndrome. Dysimmune Neuropathies 2020. [DOI: 10.1016/b978-0-12-814572-2.00002-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Alva-diaz C, Mori N, Pacheco-barrios K, Velásquez-rimachi V, Rivera-torrejon O, Huerta-rosario CA, Alarcon-ruiz CA, Meza-vega M, Quispe-zapana Y, Tagle-lostaunau I, Cam-paucar JL, Aquino-peña F, Vargas-bellina V, Guillen-tello G, Campuzano-lezama V, Vargas-nuñez GA, Lozano-vasquez LM, Mazzetti-soler PE. Guía de práctica clínica para el diagnóstico y tratamiento del paciente con síndrome de Guillain-Barré. Neurología Argentina 2020;12:36-48. [DOI: 10.1016/j.neuarg.2019.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Reynolds J, Sachs G. Autoimmune Neuropathies. Clinical Neuroimmunology 2020. [DOI: 10.1007/978-3-030-24436-1_16] [Reference Citation Analysis]
61 Atypical Manifestations in Children with Guillain Barré Syndrome. snnsj 2019. [DOI: 10.46940/snnsj.01.1001] [Reference Citation Analysis]
62 Feinisa Khairani A, Karina M, Hanum Siswanti L, Milanti Dewi M. Clinical Profile of Pediatric Guillain-Barré Syndrome: A study from National Referral Hospital in West Java, Indonesia. Biomed Pharmacol J 2019;12:2043-8. [DOI: 10.13005/bpj/1837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Al Othman B, Raabe J, Kini A, Lee AG. Update: the Miller Fisher variants of Guillain-Barré syndrome. Curr Opin Ophthalmol 2019;30:462-6. [PMID: 31567467 DOI: 10.1097/ICU.0000000000000611] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
64 Liu H, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. Brain Behav 2020;10:e01496. [PMID: 31828968 DOI: 10.1002/brb3.1496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
65 Leonhard SE, Conde RM, de Assis Aquino Gondim F, Jacobs BC. Diagnosis and treatment of Guillain-Barré syndrome during the Zika virus epidemic in Brazil: A national survey study. J Peripher Nerv Syst 2019;24:340-7. [PMID: 31746070 DOI: 10.1111/jns.12358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
66 Pham HP, Schwartz J. Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 2019;48:338-46. [PMID: 31679897 DOI: 10.1016/j.lpm.2019.03.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Bazaraa HM, Rady HI, Mohamed SA, Rabie WA, ElAnwar NH. Initial Response and Outcome of Critically Ill Children With Guillain Barre' Syndrome. Front Pediatr 2019;7:378. [PMID: 31620410 DOI: 10.3389/fped.2019.00378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Verboon C, van den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, Lingsma H, Van den Bergh P, Harbo T, Bateman K, Pereon Y, Sindrup SH, Kusunoki S, Miller J, Islam Z, Hartung HP, Chavada G, Jacobs BC, Hughes RAC, van Doorn PA; IGOS Consortium. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry 2020;91:113-21. [PMID: 31586949 DOI: 10.1136/jnnp-2019-321496] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
69 Prada V, Massa F, Salerno A, Fregosi D, Beronio A, Serrati C, Mannironi A, Mancardi G, Schenone A, Benedetti L. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study. Neurol Sci 2020;41:321-7. [DOI: 10.1007/s10072-019-04077-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
70 Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, van Doorn PA, Dourado ME, Hughes RAC, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019;15:671-83. [PMID: 31541214 DOI: 10.1038/s41582-019-0250-9] [Cited by in Crossref: 250] [Cited by in F6Publishing: 266] [Article Influence: 62.5] [Reference Citation Analysis]
71 Xu S, Wang YS, Li S, Liu HY. [Guillain-Barre syndrome complicated on post-operation with renal carcinoma and meningioma: a case report]. Beijing Da Xue Xue Bao Yi Xue Ban 2019;51:775-7. [PMID: 31420639 DOI: 10.19723/j.issn.1671-167X.2019.04.032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Vellipuram AR, Cruz-Flores S, Chaudhry MRA, Rawla P, Maud A, Rodriguez GJ, Kassar D, Piriyawat P, Qureshi MA, Khatri R. Comparative Outcomes of Respiratory Failure Associated with Common Neuromuscular Emergencies: Myasthenia Gravis versus Guillain-Barré Syndrome. Medicina (Kaunas) 2019;55:E375. [PMID: 31311172 DOI: 10.3390/medicina55070375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium. Regional variation of Guillain-Barré syndrome. Brain 2018;141:2866-77. [PMID: 30247567 DOI: 10.1093/brain/awy232] [Cited by in Crossref: 122] [Cited by in F6Publishing: 125] [Article Influence: 30.5] [Reference Citation Analysis]
74 Fadia M, Shroff S, Simpson E. Immune-Mediated Neuropathies. Curr Treat Options Neurol 2019;21. [DOI: 10.1007/s11940-019-0569-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
75 Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC; IGOS Consortium. Current treatment practice of Guillain-Barré syndrome. Neurology 2019;93:e59-76. [PMID: 31175208 DOI: 10.1212/WNL.0000000000007719] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
76 Kamate M, Detroja M, Reddy AN. Do All Children with Guillain Barré Syndrome Need Immunotherapy? Indian J Pediatr 2019;86:479-479. [DOI: 10.1007/s12098-019-02864-0] [Reference Citation Analysis]
77 Forcada AG. Neuropatías, radiculopatías y plexopatías. Medicine - Programa de Formación Médica Continuada Acreditado 2019;12:4423-4436. [DOI: 10.1016/j.med.2019.03.023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Bölükbaşi F, Ersen G, Gündüz A, Karaali-Savrun F, Yazici S, Uzun N, Akalin MA, Kiziltan ME. Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors. Noro Psikiyatr Ars 2019;56:71-4. [PMID: 30911241 DOI: 10.5152/npa.2017.18091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Benedetti L, Briani C, Beronio A, Massa F, Giorli E, Sani C, Delia P, Artioli S, Sormani MP, Mannironi A, Tartaglione A, Mancardi GL. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study. J Peripher Nerv Syst 2019;24:80-86. [DOI: 10.1111/jns.12292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
80 Esmail S. An Overview of Guillain-Barré Syndrome. NPR 2019. [DOI: 10.33805/2641-8991.113] [Reference Citation Analysis]
81 Kesici S, Tanyıldız M, Yetimakman F, Bayrakci B. A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method. J Child Neurol 2019;34:277-83. [PMID: 30696330 DOI: 10.1177/0883073819826225] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
82 Shavit-Stein E, Aronovich R, Sylantiev C, Gera O, Gofrit SG, Chapman J, Dori A. Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis. Front Neurol 2018;9:1139. [PMID: 30662428 DOI: 10.3389/fneur.2018.01139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
83 Grover KM, Sripathi N. Neuromuscular Emergencies. Emergencies in Neurology 2019. [DOI: 10.1007/978-981-13-7381-7_5] [Reference Citation Analysis]
84 Crean PM, Tirupathi S. Essentials of Neurology and Neuromuscular Disorders. A Practice of Anesthesia for Infants and Children 2019. [DOI: 10.1016/b978-0-323-42974-0.00024-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Rodríguez Y, Chang C, González-bravo DC, Gershwin ME, Anaya J. Guillain-Barré Syndrome. Contemporary Clinical Neuroscience 2019. [DOI: 10.1007/978-3-030-19515-1_24] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Zuercher AW, Berger M, Bolli R, Vonarburg C, Spycher M, Shebl A, Spirig R, Kempf C, Käsermann F, Miescher S. Plasma-Derived Immunoglobulins. Nijkamp and Parnham's Principles of Immunopharmacology 2019. [DOI: 10.1007/978-3-030-10811-3_20] [Reference Citation Analysis]
87 Bril EV, Popugaev KA, Udalov YD, Parinov OV, Zabelin MV, Samoilov AS. Critical Care Management of Guillain-Barré Syndrome. Textbook of Neuroanesthesia and Neurocritical Care 2019. [DOI: 10.1007/978-981-13-3390-3_4] [Reference Citation Analysis]
88 Hannawi Y, Shah JN, Haji S, Mirski MA. Critical Care Neurology. Atlas of Clinical Neurology 2019. [DOI: 10.1007/978-3-030-03283-8_4] [Reference Citation Analysis]
89 Gramespacher H, Doppler C, Hesse MD, Stetefeld HR. Fisher-Bickerstaff- und Guillain-Barré-Überlappungssyndrome im intensivstationären Management. DGNeurologie 2019;2:8-14. [DOI: 10.1007/s42451-018-0038-y] [Reference Citation Analysis]
90 Benedetti L, Briani C, Beronio A, Massa F, Giorli E, Sani C, Delia P, Artioli S, Sormani MP, Mannironi A, Tartaglione A, Mancardi GL. Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study. J Peripher Nerv Syst 2019;24:80-6. [PMID: 30421471 DOI: 10.1111/jns.12292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 2018;23:210-5. [PMID: 30151941 DOI: 10.1111/jns.12286] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
92 Chang AY, Lynch R, Martins K, Encinales L, Cadena Bonfanti AÁ, Pacheco N, Reid SP, Lara Sarabia OE, González Torres HJ, Mejia Castillo S, Barrios Taborda O, Alarcon Gomez M, Guerra Duran B, Martinez Giraldo V, Benitez Ospino A, Porras A, Mendoza AR, Mantus G, Li G, Peng J, Kamalapathy P, Avendaño Echavez LG, Dowd KA, Rengifo-Pardo M, Barraza PP, Jiménez Hernàndez D, González Coba A, De La Hoz Mendoza K, Bethony JM, Simon GL. Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome. Emerg Microbes Infect 2018;7:148. [PMID: 30131486 DOI: 10.1038/s41426-018-0151-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
93 Donofrio PD. Guillain-Barré Syndrome. Continuum (Minneap Minn) 2017;23:1295-309. [PMID: 28968363 DOI: 10.1212/CON.0000000000000513] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
94 Axelsson M, Sjögren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Acta Neurol Scand 2018;138:143-50. [PMID: 29624650 DOI: 10.1111/ane.12927] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
95 Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother 2018;14:2568-79. [PMID: 29953326 DOI: 10.1080/21645515.2018.1493415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
96 Zhang Y, Zhao Y, Wang Y. Prognostic factors of Guillain-Barré syndrome: a 111-case retrospective review. Chin Neurosurg J 2018;4:14. [PMID: 32922875 DOI: 10.1186/s41016-018-0122-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
97 Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R, Vitaliti G. Biological Drugs in Guillain-Barré Syndrome: An Update. Curr Neuropharmacol 2017;15:938-50. [PMID: 27964705 DOI: 10.2174/1570159X14666161213114904] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
98 Restrepo-jiménez P, Rodríguez Y, González P, Chang C, Gershwin ME, Anaya J. The immunotherapy of Guillain-Barré syndrome. Expert Opinion on Biological Therapy 2018;18:619-31. [DOI: 10.1080/14712598.2018.1468885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
99 Donghui Shen, Fengna Chu, Yue Lang, Yunlong Geng, Xiangyu Zheng, Jie Zhu, Kangding Liu. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis. Mediators Inflamm 2018;2018:4286364. [PMID: 29853789 DOI: 10.1155/2018/4286364] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 3.4] [Reference Citation Analysis]
100 Shen D, Chu F, Lang Y, Geng Y, Zheng X, Zhu J, Liu K. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis. Mediators Inflamm 2018;2018:4286364. [PMID: 29853789 DOI: 10.1155/2018/4286364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
101 Chen X, Guo Y, Han R, Liu H, Ding Y, Shi Y, Kong D, Ma X. Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines. Cell Immunol 2018;329:41-9. [PMID: 29724464 DOI: 10.1016/j.cellimm.2018.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
102 Shrivastava M, Nehal S, Seema N. Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India. Indian J Med Res 2017;145:203-8. [PMID: 28639596 DOI: 10.4103/ijmr.IJMR_995_14] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
103 Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst 2017;22:68-76. [PMID: 28406555 DOI: 10.1111/jns.12209] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 14.6] [Reference Citation Analysis]
104 Hughes RAC, Cornblath DR, Willison HJ. Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain 2016;139:3041-7. [PMID: 29106487 DOI: 10.1093/brain/aww247] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
105 Siddiqi ZA, Courtney K, Hanna K, Mondou E, Bril V. Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study. Can J Neurol Sci 2017;44:711-7. [PMID: 29391076 DOI: 10.1017/cjn.2017.205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Samiotis I, Baikoussis NG, Patris V, Argiriou M, Dedeilias P, Charitos C. Coronary artery bypass grafting and paraparesis; is there a correlation? Cardiovasc J Afr 2018;29:e6-8. [PMID: 29582882 DOI: 10.5830/CVJA-2017-014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Hüner EA, Dai AI, Demiryürek AT. Association of Neutrophil/Lymphocyte Ratio With Intravenous Immunoglobulin Treatment in Children With Guillain-Barré Syndrome. J Child Neurol 2018;33:164-7. [DOI: 10.1177/0883073817748109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
108 Novak P, Šmid S, Vidmar G. Rehabilitation of Guillain-Barré syndrome patients: an observational study. Int J Rehabil Res 2017;40:158-63. [PMID: 28368871 DOI: 10.1097/MRR.0000000000000225] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
109 Wang Y. Rehabilitation of Patients With Neuropathies. Braddom's Rehabilitation Care: A Clinical Handbook 2018. [DOI: 10.1016/b978-0-323-47904-2.00041-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
110 Imbach P. Manual of Intravenous and Subcutaneous IgG Indications in Autoimmune Diseases. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_4] [Reference Citation Analysis]
111 Guan Z, Shang L, Zhang W, Guo Y, Xue Y, Li X, Gong Y, Liu X. A rating scale for the severity of Guillain-Barré syndrome. Acta Neurol Scand 2017;136:680-7. [PMID: 28612931 DOI: 10.1111/ane.12786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
112 Pianka K, Rothman A, Tripathi A. Status of diagnostics for three arbovirus infections in resource-limited settings. Technology 2017;05:115-28. [DOI: 10.1142/s2339547817300025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
113 Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD. Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study. Pilot Feasibility Stud 2017;3:40. [PMID: 28975040 DOI: 10.1186/s40814-017-0185-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
114 Nagappa M, Rahul W, Sinha S, Bindu PS, Mathuranath PS, Rao S, Periyavan S, Umamaheshwara Rao GS, Taly AB. Guillain Barre Syndrome in the elderly: Experience from a tertiary-care hospital in India. J Clin Neurosci 2017;46:45-9. [PMID: 28890042 DOI: 10.1016/j.jocn.2017.08.048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
115 Wang Y, Lang W, Zhang Y, Ma X, Zhou C, Zhang HL. Long-term prognosis of Guillain-Barré syndrome not determined by treatment options? Oncotarget 2017;8:79991-80001. [PMID: 29108381 DOI: 10.18632/oncotarget.20620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
116 Tang HY, Chiu DT, Lin JF, Huang CY, Chang KH, Lyu RK, Ro LS, Kuo HC, Cheng ML, Chen CM. Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome. Sci Rep 2017;7:8140. [PMID: 28811529 DOI: 10.1038/s41598-017-08338-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
117 Nayak R. Practical approach to the patient with acute neuromuscular weakness. World J Clin Cases 2017; 5(7): 270-279 [PMID: 28798922 DOI: 10.12998/wjcc.v5.i7.270] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
118 Gonsalvez DG, Tran G, Fletcher JL, Hughes RA, Hodgkinson S, Wood RJ, Yoo SW, De Silva M, Agnes WW, McLean C, Kennedy P, Kilpatrick TJ, Murray SS, Xiao J. A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination. eNeuro 2017;4:ENEURO. [PMID: 28680965 DOI: 10.1523/ENEURO.0142-17.2017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
119 Pacheco LD, Saad AF, Hankins GD, Chiosi G, Saade G. Guillain-Barré Syndrome in Pregnancy. Obstet Gynecol 2016;128:1105-10. [PMID: 27741183 DOI: 10.1097/AOG.0000000000001716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
120 Hon P. Intensice care in patients with Guillain-Barré syndrome. Neurol pro Praxi 2017;18:98-102. [DOI: 10.36290/neu.2017.070] [Reference Citation Analysis]
121 Meganathan A, Ramadoss K. A STUDY ON THE CLINICAL AND ELECTRODIAGNOSTIC PROFILE OF GBS AND ITS CORRELATION WITH EARLY PREDICTORS OF PROGNOSIS. jemds 2017;6:2027-2032. [DOI: 10.14260/jemds/2017/442] [Reference Citation Analysis]
122 Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017;2:CD001798. [PMID: 28241090 DOI: 10.1002/14651858.CD001798.pub3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
123 Liu H, Wan C, Ding Y, Han R, He Y, Xiao J, Hao J. PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production. FASEB J 2017;31:1756-66. [PMID: 28096232 DOI: 10.1096/fj.201601147R] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
124 Wang Q, Xing C, Hao Y, Shi Q, Qi Z, Lv Z, Song Y, Xu P, Feng X, Zhang L, Zhang Y, Wang Y, Yuki N. Memory B cells in Guillain-Barré syndrome. J Neuroimmunol 2017;305:1-4. [PMID: 28284328 DOI: 10.1016/j.jneuroim.2017.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
125 Backert S, Tegtmeyer N, Cróinín TÓ, Boehm M, Heimesaat MM. Human campylobacteriosis. Campylobacter 2017. [DOI: 10.1016/b978-0-12-803623-5.00001-0] [Cited by in Crossref: 29] [Article Influence: 4.8] [Reference Citation Analysis]
126 Bidkar P, Satya Prakash M. Neuromuscular Disorders. Essentials of Neuroanesthesia 2017. [DOI: 10.1016/b978-0-12-805299-0.00045-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Grebenciucova E, Rezania K. Immunopathogenesis and Treatment of Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. Inflammatory Disorders of the Nervous System 2017. [DOI: 10.1007/978-3-319-51220-4_10] [Reference Citation Analysis]
128 Esposito S, Longo MR. Guillain–Barré syndrome. Autoimmunity Reviews 2017;16:96-101. [DOI: 10.1016/j.autrev.2016.09.022] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 14.7] [Reference Citation Analysis]
129 Ramakrishnan S, Mustare V, Philip M, Thennarasu K, Periyavan S. Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis. Ann Indian Acad Neurol 2017;20:372-7. [PMID: 29184340 DOI: 10.4103/aian.AIAN_242_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
130 Rink C, Görtzen A, Veh RW, Prüss H. Serum antibodies targeting neurons of the monoaminergic systems in Guillain-Barré syndrome. Journal of the Neurological Sciences 2017;372:318-23. [DOI: 10.1016/j.jns.2016.11.078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
131 Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017;139:S1-S46. [PMID: 28041678 DOI: 10.1016/j.jaci.2016.09.023] [Cited by in Crossref: 325] [Cited by in F6Publishing: 345] [Article Influence: 46.4] [Reference Citation Analysis]
132 Caffarelli M, Kimia AA, Torres AR. Acute Ataxia in Children: A Review of the Differential Diagnosis and Evaluation in the Emergency Department. Pediatric Neurology 2016;65:14-30. [DOI: 10.1016/j.pediatrneurol.2016.08.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
133 Pritchard J, Hughes RA, Hadden RD, Brassington R. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016;11:CD008630. [PMID: 27846348 DOI: 10.1002/14651858.CD008630.pub4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
134 Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2017;88:346-52. [PMID: 27837102 DOI: 10.1136/jnnp-2016-314862] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
135 Jasti AK, Selmi C, Sarmiento-monroy JC, Vega DA, Anaya J, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Review of Clinical Immunology 2016;12:1175-1189. [DOI: 10.1080/1744666x.2016.1193006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
136 Léger JM, Guimarães-Costa R, Muntean C. Immunotherapy in Peripheral Neuropathies. Neurotherapeutics 2016;13:96-107. [PMID: 26602549 DOI: 10.1007/s13311-015-0401-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
137 Ghonemy T. Outcomes of Therapeutic Plasma Exchange; One Year Single Center Experience. UNOAJ 2016;3. [DOI: 10.15406/unoaj.2016.03.00096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Ding Y, Han R, Jiang W, Xiao J, Liu H, Chen X, Li X, Hao J. Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats. J Immunol 2016;197:3831-40. [PMID: 27798164 DOI: 10.4049/jimmunol.1601083] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
139 Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol 2016;12:1175-89. [PMID: 27292311 DOI: 10.1080/1744666X.2016.1193006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
140 Han R, Gao J, Zhai H, Xiao J, Ding Y, Hao J. RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages. Experimental Neurology 2016;280:106-14. [DOI: 10.1016/j.expneurol.2016.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
141 Léger J, Haghi B, Guimarães-costa R. Syndrome de Guillain-Barré : prise en charge thérapeutique. Bulletin de l'Académie Nationale de Médecine 2016;200:1101-1113. [DOI: 10.1016/s0001-4079(19)30653-3] [Reference Citation Analysis]
142 Han R, Xiao J, Zhai H, Hao J. Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages. J Neuroinflammation 2016;13:97. [PMID: 27142843 DOI: 10.1186/s12974-016-0559-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
143 Ravikumar S, Poysophon P, Poblete R, Kim-Tenser M. A Case of Acute Motor Axonal Neuropathy Mimicking Brain Death and Review of the Literature. Front Neurol 2016;7:63. [PMID: 27199887 DOI: 10.3389/fneur.2016.00063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
144 Alhefzi M, Aycart M, Bueno E, Kueckelhaus M, Fischer S, Snook R, Sharfuddin A, Hadad I, Malla P, Amato A, Pomahac B, Marty F. Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation. Transpl Infect Dis 2016;18:288-92. [DOI: 10.1111/tid.12516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
145 Godoy DA, Rabinstein A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? Arq Neuropsiquiatr 2015;73:848-51. [PMID: 26465402 DOI: 10.1590/0004-282X20150136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
146 Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717-727. [PMID: 26948435 DOI: 10.1016/s0140-6736(16)00339-1] [Cited by in Crossref: 716] [Cited by in F6Publishing: 754] [Article Influence: 102.3] [Reference Citation Analysis]
147 van Leeuwen N, Lingsma HF, Vanrolleghem AM, Sturkenboom MC, van Doorn PA, Steyerberg EW, Jacobs BC. Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome. PLoS One 2016;11:e0143837. [PMID: 26859880 DOI: 10.1371/journal.pone.0143837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
148 Wu X, Zhang B, Li C, Shen D, Liu K, Zhu J, Zhang HL. Short-Term Prognosis of Mechanically Ventilated Patients With Guillain-Barré Syndrome Is Worsened by Corticosteroids as an Add-On Therapy. Medicine (Baltimore) 2015;94:e1898. [PMID: 26512609 DOI: 10.1097/MD.0000000000001898] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
149 Živković S. Intravenous immunoglobulin in the treatment of neurologic disorders. Acta Neurol Scand 2016;133:84-96. [PMID: 25997034 DOI: 10.1111/ane.12444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
150 Lametery E, Dubois-teklali F, Millet A, Manel V. Le syndrome pharyngo-cervico-brachial : un tableau de syndrome de Guillain-Barré atypique avec paralysie bulbaire sévère. Archives de Pédiatrie 2016;23:176-9. [DOI: 10.1016/j.arcped.2015.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Cibulčík F. Guillain-Barré polyradiculoneuritis. Neurol pro Praxi 2016;17:11-5. [DOI: 10.36290/neu.2016.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
152 Morgan C, Wakerley B. Acute peripheral weakness and suspected Guillain-Barré syndrome. Br J Hosp Med (Lond) 2015;76:C178-81. [PMID: 26646343 DOI: 10.12968/hmed.2015.76.12.C178] [Reference Citation Analysis]
153 Loshaj-shala A, Regazzoni L, Daci A, Orioli M, Brezovska K, Panovska AP, Beretta G, Suturkova L. Guillain Barré syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins. Journal of Neuroimmunology 2015;289:168-76. [DOI: 10.1016/j.jneuroim.2015.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
154 Shinchi H, Yuki N, Ishida H, Hirata K, Wakao M, Suda Y. Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome. PLoS One 2015;10:e0137966. [PMID: 26378448 DOI: 10.1371/journal.pone.0137966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Asthana P, Vong JS, Kumar G, Chang RC, Zhang G, Sheikh KA, Ma CH. Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach. Mol Neurobiol 2016;53:4981-91. [PMID: 26374552 DOI: 10.1007/s12035-015-9430-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
156 Kim HJ, Lee EJ, Lee SH, Chang GT. A Literature Study on Treatment of Guillain-Barre Syndrome Based on Traditional Chinese Medicine Journals. The Journal of Korean Oriental Pediatrics 2015;29:21-31. [DOI: 10.7778/jpkm.2015.29.3.021] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Kim S, Joo J, Hong YB, Choi B. Ultrasonography-guided transplantation facilitates perineural delivery of stem cells. Animal Cells and Systems 2015;19:269-73. [DOI: 10.1080/19768354.2015.1053521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 White CM, Hadden RD, Robert-Lewis SF, McCrone PR, Petty JL. Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy. BMC Neurol 2015;15:147. [PMID: 26293925 DOI: 10.1186/s12883-015-0398-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
159 Blum S, Csurhes P, McCombe P. The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis. J Neuroimmunol 2015;285:53-6. [PMID: 26198918 DOI: 10.1016/j.jneuroim.2015.05.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
160 Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China. PLoS One 2015;10:e0133520. [PMID: 26200903 DOI: 10.1371/journal.pone.0133520] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
161 Takahashi R, Yuki N. Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome. Sci Rep 2015;5:10809. [PMID: 26194472 DOI: 10.1038/srep10809] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
162 Dimachkie MM, Saperstein DS. Acquired immune demyelinating neuropathies. Continuum (Minneap Minn) 2014;20:1241-60. [PMID: 25299280 DOI: 10.1212/01.CON.0000455883.91426.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
163 Miller ER, Moro PL, Cano M, Shimabukuro TT. Deaths following vaccination: What does the evidence show? Vaccine 2015;33:3288-92. [PMID: 26004568 DOI: 10.1016/j.vaccine.2015.05.023] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
164 Cabasson S, Tardieu M, Meunier A, Rouanet-Larriviere MF, Boulay C, Pedespan JM. Childhood CIDP: Study of 31 patients and comparison between slow and rapid-onset groups. Brain Dev 2015;37:943-51. [PMID: 25921353 DOI: 10.1016/j.braindev.2015.04.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
165 Bourque PR, Chardon JW, Massie R. Autoimmune peripheral neuropathies. Clin Chim Acta 2015;449:37-42. [PMID: 25748038 DOI: 10.1016/j.cca.2015.02.039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
166 Le Guennec L, Brisset M, Viala K, Essardy F, Maisonobe T, Rohaut B, Demeret S, Bolgert F, Weiss N. Post-traumatic stress symptoms in Guillain-Barré syndrome patients after prolonged mechanical ventilation in ICU: a preliminary report: Guennec. J Peripher Nerv Syst 2014;19:218-23. [DOI: 10.1111/jns.12087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
167 Loshaj-shala A, Poceva Panovska A, Brezovska K, Beretta G, Suturkova L, Apostolski S. Involvement of serum HSP 70 in Guillain-Barré Syndrome: An exploratory study and a review of current literature. Maced Pharm Bull 2015;61:61-7. [DOI: 10.33320/maced.pharm.bull.2015.61.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Davis D, Mendoza P. Rehabilitation of Patients with Peripheral Nerve Injuries. Nerves and Nerve Injuries 2015. [DOI: 10.1016/b978-0-12-802653-3.00099-3] [Reference Citation Analysis]
169 Lin JH, Tu KH, Chang CH, Chen YC, Tian YC, Yu CC, Hung CC, Fang JT, Yang CW, Chang MY. Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome. Transfus Apher Sci 2015;52:78-83. [PMID: 25544386 DOI: 10.1016/j.transci.2014.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
170 Ye Y, Li S, Li Y. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome: Comparison of PE and IVIg for GBS. Transfusion Med 2015;25:79-84. [DOI: 10.1111/tme.12169] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
171 Berger M, McCallus DE, Lin CS. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst 2013;18:275-96. [PMID: 24200120 DOI: 10.1111/jns5.12048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
172 Ma YY, Zhang L, Zhang DL, Liu WS. Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report. Oncol Lett 2014;8:2695-8. [PMID: 25360176 DOI: 10.3892/ol.2014.2541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
173 Ritzenthaler T, Sharshar T, Orlikowski D. Síndrome de Guillain-Barré. EMC - Anestesia-Reanimación 2014;40:1-8. [DOI: 10.1016/s1280-4703(14)68953-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Ritzenthaler T, Sharshar T, Orlikowski D. Sindrome di Guillain-Barré. EMC - Anestesia-Rianimazione 2014;19:1-7. [DOI: 10.1016/s1283-0771(14)68864-2] [Reference Citation Analysis]
175 Hou HQ, Miao J, Feng XD, Han M, Song XJ, Guo L. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin. BMC Neurol 2014;14:202. [PMID: 25315010 DOI: 10.1186/s12883-014-0202-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
176 Tassart G, Balbeur S, Deltombe T, Tintillier M, Cuvelier Ch. Guillain-Barré syndrome associated with Puumula Hantavirus infection. Acta Clin Belg 2014;69:371-4. [PMID: 25092197 DOI: 10.1179/0001551214Z.00000000085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
177 Nyati KK, Prasad KN. Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome. Mediators Inflamm 2014;2014:758639. [PMID: 25614713 DOI: 10.1155/2014/758639] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
178 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014;:CD002063. [PMID: 25238327 DOI: 10.1002/14651858.CD002063.pub6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 138] [Article Influence: 10.0] [Reference Citation Analysis]
179 van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82. [DOI: 10.1038/nrneurol.2014.121] [Cited by in Crossref: 525] [Cited by in F6Publishing: 556] [Article Influence: 58.3] [Reference Citation Analysis]
180 Usuki S, O'Brien D, Rivner MH, Yu RK. A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples. J Immunol Methods 2014;408:52-63. [PMID: 24861939 DOI: 10.1016/j.jim.2014.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
181 García-reynoso MJ, Veramendi-espinoza LE, Ruiz-garcia HJ. Paresia ascendente como comienzo de inusual asociación entre miopatía autoinmune necrosante y lupus eritematoso sistémico. Reumatología Clínica 2014;10:183-6. [DOI: 10.1016/j.reuma.2013.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
182 García-reynoso MJ, Veramendi-espinoza LE, Ruiz-garcia HJ. Ascending Paresis as Presentation of an Unusual Association Between Necrotizing Autoimmune Myopathy and Systemic Lupus Erythematosus. Reumatología Clínica (English Edition) 2014;10:183-186. [DOI: 10.1016/j.reumae.2013.12.015] [Reference Citation Analysis]
183 Yuki N. Rabbit Model of Guillain-Barré Syndrome. Campylobacter 2014. [DOI: 10.1128/9781555815554.ch22] [Reference Citation Analysis]
184 Disease-specific neurorehabilitation systems. Textbook of Neural Repair and Rehabilitation 2014. [DOI: 10.1017/cbo9780511995590.044] [Reference Citation Analysis]
185 Lehmann HC, Köller H, Hartung H. Neuromuscular rehabilitation: diseases of the motor neuron, peripheral nerve, neuromuscular junction, and the muscle. Textbook of Neural Repair and Rehabilitation 2014. [DOI: 10.1017/cbo9780511995590.052] [Reference Citation Analysis]
186 Mateen FJ, Bahl S, Khera A, Sutter RW. Detection of diphtheritic polyneuropathy by acute flaccid paralysis surveillance, India. Emerg Infect Dis 2013;19:1368-73. [PMID: 23965520 DOI: 10.3201/eid1909.130117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
187 Darweesh SKL, Polinder S, Mulder MJHL, Baena CP, van Leeuwen N, Franco OH, Jacobs BC, van Doorn PA. Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst 2014;19:24-35. [DOI: 10.1111/jns5.12051] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
188 Kishore CK, Vijayabhaskar J, Vishnu Vardhan R, Sainaresh VV, Sriramnaveen P, Sridhar AV, Varalaxmi B, Sandeep P, Ram R, Vengamma B, Siva Kumar V. Management of Guillain-Barré syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India. Ren Fail 2014;36:732-6. [PMID: 24593239 DOI: 10.3109/0886022X.2014.890859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
189 Karaca S, Kozanoğlu İ, Karakurum Göksel B, Karataş M, Tan M, Yerdelen VD, Giray S, Arlier Z. Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years. Noro Psikiyatr Ars 2014;51:63-8. [PMID: 28360597 DOI: 10.4274/npa.y6879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
190 Kaida K, Kusunoki S. Guillain–Barré syndrome: update on immunobiology and treatment. Expert Review of Neurotherapeutics 2014;9:1307-19. [DOI: 10.1586/ern.09.77] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
191 Uncini A, Yuki N. Electrophysiologic and immunopathologic correlates in Guillain–Barré syndrome subtypes. Expert Review of Neurotherapeutics 2014;9:869-84. [DOI: 10.1586/ern.09.43] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
192 Bansal VK, Meriggioli MN. Immunotherapy in the Treatment of Autoimmune Neuromuscular Diseases. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Susuki K. Node of Ranvier Disruption: A Key Pathophysiology in Immune-Mediated Neuropathies. Schwann Cell Development and Pathology 2014. [DOI: 10.1007/978-4-431-54764-8_8] [Reference Citation Analysis]
194 Piccione EA, Salame K, Katirji B. Guillain-Barré Syndrome and Related Disorders. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_28] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
195 Tucci M, Lacroix J, Gauvin F, Toledano B, Robitaille N. Transfusion Medicine. Pediatric Critical Care Medicine 2014. [DOI: 10.1007/978-1-4471-6416-6_19] [Reference Citation Analysis]
196 Shadvar K, Eslampoor Y. Progressive Paraparesis after CABG Surgery. J Cardiovasc Thorac Res 2013;5:37-9. [PMID: 24251008 DOI: 10.5681/jcvtr.2013.008] [Reference Citation Analysis]
197 Paton E, Baldwin IC. Plasma exchange in the intensive care unit: a 10 year retrospective audit. Aust Crit Care. 2014;27:139-144. [PMID: 24252643 DOI: 10.1016/j.aucc.2013.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
198 McNair ND. Treatment of Guillain-Barré syndrome. J Infus Nurs 2013;36:397-400. [PMID: 24202119 DOI: 10.1097/NAN.0000000000000011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
199 Lehmann HC, Hughes RA, Kieseier BC, Hartung HP. Recent developments and future directions in Guillain-Barré syndrome. J Peripher Nerv Syst 2012;17 Suppl 3:57-70. [PMID: 23279434 DOI: 10.1111/j.1529-8027.2012.00433.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
200 Harms M. Inpatient management of guillain-barré syndrome. Neurohospitalist 2011;1:78-84. [PMID: 23983841 DOI: 10.1177/1941875210396379] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
201 Nyati KK, Nyati R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. Biomed Res Int 2013;2013:852195. [PMID: 24000328 DOI: 10.1155/2013/852195] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 10.4] [Reference Citation Analysis]
202 Navani V, Webster D, Williams SK, Agranoff D. Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma. BMJ Case Rep 2013;2013:bcr2013009700. [PMID: 23729714 DOI: 10.1136/bcr-2013-009700] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Ylipalosaari P, Ala-kokko TI, Tuominen H, Syrjälä H. Guillain–Barré syndrome and ulceroglandular tularemia. Infection 2013;41:881-3. [DOI: 10.1007/s15010-013-0466-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
204 Wang X, Ma C, Wu J, Zhu J. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models. J Neurosci Res 2013;91:871-81. [PMID: 23653308 DOI: 10.1002/jnr.23233] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
205 van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med 2013;42:e193-201. [PMID: 23628447 DOI: 10.1016/j.lpm.2013.02.328] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
206 Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:299-326. [PMID: 22850724 DOI: 10.2183/pjab.88.299] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
207 Woodward S. Guillain-Barré syndrome. British Journal of Neuroscience Nursing 2013;9:59-61. [DOI: 10.12968/bjnn.2013.9.2.59] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2013;:CD008630. [PMID: 23450584 DOI: 10.1002/14651858.CD008630.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
209 Fujimura H. The Guillain-Barré syndrome. Handb Clin Neurol 2013;115:383-402. [PMID: 23931791 DOI: 10.1016/B978-0-444-52902-2.00021-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
210 Greenberg SB, Tokarczyk AJ, Zahed C, Coursin DB. Endocrine Issues in Neurocritical Care. Textbook of Neurointensive Care 2013. [DOI: 10.1007/978-1-4471-5226-2_15] [Reference Citation Analysis]
211 Uribarri López M, Aguilera Celorrio L, Miguel Martínez C, Yuste Del Valle S. [Guillain-Barré syndrome in the critical care unit in the last 10 years]. Rev Esp Anestesiol Reanim 2013;60:257-62. [PMID: 23260991 DOI: 10.1016/j.redar.2012.10.014] [Reference Citation Analysis]
212 Keyrouz SG, Diringer MN. Year in review 2011: Critical Care--Neurocritical care. Crit Care 2012;16:245. [PMID: 23256871 DOI: 10.1186/cc11825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
213 Yosef N, Ubogu EE. α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. J Cell Physiol 2012;227:3857-75. [PMID: 22552879 DOI: 10.1002/jcp.24100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
214 Omejec G, Podnar S. Retrospective analysis of Slovenian patients with Guillain-Barré syndrome. J Peripher Nerv Syst 2012;17:217-9. [PMID: 22734909 DOI: 10.1111/j.1529-8027.2012.00397.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
215 Sarkar UK, Menon L, Sarbapalli D, Pal R, Zaman FA, Kar S, Singh J, Mondal M, Mukherjee S. Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata. J Nat Sci Biol Med 2011;2:211-5. [PMID: 22346239 DOI: 10.4103/0976-9668.92320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012;:CD001798. [PMID: 22786475 DOI: 10.1002/14651858.CD001798.pub2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
217 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012;:CD002063. [PMID: 22786476 DOI: 10.1002/14651858.CD002063.pub5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
218 Duguet A, Rabbat A, Demeret S, Le Floch H. Les maladies neuromusculaires aiguës. Revue des Maladies Respiratoires Actualités 2012;4:168-171. [DOI: 10.1016/s1877-1203(12)70218-5] [Reference Citation Analysis]
219 Baker MG, Kvalsvig A, Zhang J, Lake R, Sears A, Wilson N. Declining Guillain-Barré syndrome after campylobacteriosis control, New Zealand, 1988-2010. Emerg Infect Dis 2012;18:226-33. [PMID: 22304786 DOI: 10.3201/eid1802.111126] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
220 Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis 2010;12:55-61. [PMID: 21386771 DOI: 10.1097/CND.0b013e3181f3dbbf] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
221 Barlinn J, Feet B, Saugstad O. Når nervesystemet påvirkes og hjertet stanser. Tidsskriftet 2012;132:432-432. [DOI: 10.4045/tidsskr.11.1392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Wijdicks EFM. First Clinical Studies and Trials. Famous First Papers for the Neurointensivist 2012. [DOI: 10.1007/978-1-4614-3182-4_6] [Reference Citation Analysis]
223 Stangel M. New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord 2008;1:52-61. [PMID: 21180569 DOI: 10.1177/1756285608095747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
224 van Doorn PA, Kuitwaard K, Jacobs BC. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst 2011;16 Suppl 1:38-40. [PMID: 21696496 DOI: 10.1111/j.1529-8027.2011.00304.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
225 Mausberg AK, Meyer Zu Hörste G, Dehmel T, Stettner M, Lehmann HC, Sheikh KA, Kieseier BC. Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages. PLoS One 2011;6:e26280. [PMID: 22043313 DOI: 10.1371/journal.pone.0026280] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
226 . Neurointensive care. Core Topics in Neuroanaesthesia and Neurointensive Care 2011. [DOI: 10.1017/cbo9780511977558.019] [Reference Citation Analysis]
227 Hirsch N, Howard R. Neuromuscular disorders. Core Topics in Neuroanaesthesia and Neurointensive Care 2011. [DOI: 10.1017/cbo9780511977558.027] [Reference Citation Analysis]
228 Mateen FJ, Cornblath DR, Jafari H, Shinohara RT, Khandit D, Ahuja B, Bahl S, Sutter RW. Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria. Vaccine 2011;29:9697-701. [PMID: 22001121 DOI: 10.1016/j.vaccine.2011.09.123] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
229 Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Sørensen PS, Udd B. Intravenous Immunoglobulin in the Treatment of Neurological Diseases. European Handbook of Neurological Management 2011. [DOI: 10.1002/9781444346268.ch9] [Reference Citation Analysis]
230 Kamihiro N, Higashigawa M, Yamamoto T, Yoshino A, Sakata K, Nashida Y, Maji T, Fujiwara T, Inoue M. Acute motor-sensory axonal Guillain-Barré syndrome with unilateral facial nerve paralysis after rotavirus gastroenteritis in a 2-year-old boy. J Infect Chemother 2012;18:119-23. [PMID: 21915637 DOI: 10.1007/s10156-011-0300-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
231 Stangel M, Gold R. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010]. Nervenarzt 2011;82:415-6, 418, 420 passim. [PMID: 20577707 DOI: 10.1007/s00115-010-3059-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
232 Hughes RA. Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome. Crit Care 2011;15:174. [PMID: 21888680 DOI: 10.1186/cc10312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
233 Lehmann HC, Meyer Zu Horste G, Kieseier BC, Hartung HP. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009;2:261-81. [PMID: 21179533 DOI: 10.1177/1756285609104792] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
234 El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011;15:R164. [PMID: 21745374 DOI: 10.1186/cc10305] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
235 Hughes RA, Swan AV, van Doorn PA. Cochrane Review: Intravenous immunoglobulin for Guillain-Barré syndrome. Evid -Based Child Health 2011;6:1176-231. [DOI: 10.1002/ebch.810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
236 Shahrizaila N, Yuki N. Clinical prognostic scales in Guillain–Barré syndrome. Nat Rev Neurol 2011;7:362-363. [DOI: 10.1038/nrneurol.2011.93] [Reference Citation Analysis]
237 Wang Q, Xiang Y, Yu K, Li C, Wang J, Xiao L. Multiple cranial neuropathy variant of guillain-barré syndrome: A case series: Cranial Variant of GBS. Muscle Nerve 2011;44:252-7. [DOI: 10.1002/mus.22043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
238 Meyer zu Hörste G, Mausberg AK, Müller JI, Lehmann HC, Löber S, Gmeiner P, Hartung HP, Stüve O, Korth C, Kieseier BC. Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules. PLoS One 2011;6:e21223. [PMID: 21698177 DOI: 10.1371/journal.pone.0021223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
239 Spalice A, Parisi P, Papetti L, Nicita F, Ursitti F, Del Balzo F, Properzi E, Verrotti A, Ruggieri M, Iannetti P. Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update. Curr Neuropharmacol 2010;8:135-48. [PMID: 21119885 DOI: 10.2174/157015910791233141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
240 Kuhle J, Petzold A. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases. Expert Opinion on Medical Diagnostics 2011;5:333-46. [DOI: 10.1517/17530059.2011.578624] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
241 Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res 2011;11:101. [PMID: 21575219 DOI: 10.1186/1472-6963-11-101] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
242 Grozdanova A, Apostolski S, Suturkova L. The role of molecular mimicry in the etiology of Guillain Barré Syndrome. Maced Pharm Bull 2011;56:3-12. [DOI: 10.33320/maced.pharm.bull.2010.56.001] [Reference Citation Analysis]
243 Shahrizaila N, Yuki N. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opinion on Pharmacotherapy 2011;12:1551-60. [DOI: 10.1517/14656566.2011.564160] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
244 Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database Syst Rev 2011;:CD008630. [PMID: 21412923 DOI: 10.1002/14651858.CD008630.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
245 Walgaard C, Jacobs BC, van Doorn PA. Emerging drugs for Guillain-Barré syndrome. Expert Opinion on Emerging Drugs 2010;16:105-20. [DOI: 10.1517/14728214.2011.531699] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
246 Simmons Z. Treatment and Management of Autoimmune Neuropathies. Neuromuscular Disorders: Treatment and Management. Elsevier; 2011. pp. 215-35. [DOI: 10.1016/b978-1-4377-0372-6.00014-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
247 Orlikowski D, Sharshar T. Poliradicolonevrite acuta: la sindrome di Guillain-Barré. EMC - AKOS - Trattato di Medicina 2011;13:1-7. [DOI: 10.1016/s1634-7358(11)70645-3] [Reference Citation Analysis]
248 Craig A, Richardson JK. Rehabilitation of Patients with Neuropathies. Physical Medicine and Rehabilitation. Elsevier; 2011. pp. 1065-95. [DOI: 10.1016/b978-1-4377-0884-4.10047-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Mcguire JL. Neuromuscular Disorders. Netter's Pediatrics 2011. [DOI: 10.1016/b978-1-4377-1155-4.00081-x] [Reference Citation Analysis]
250 Juel VC, Bleck TP. Neuromuscular Disorders in the ICU. Textbook of Critical Care. Elsevier; 2011. pp. 212-9. [DOI: 10.1016/b978-1-4377-1367-1.00037-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
251 Mitchell CW, Bertorini TE. Principles and Guidelines of Immunotherapy in Neuromuscular Disorders. Neuromuscular Disorders: Treatment and Management 2011. [DOI: 10.1016/b978-1-4377-0372-6.00007-4] [Reference Citation Analysis]
252 Stangel M, Pul R, Skripuletz T, Trebst C, Voss E, Gudi V. Remyelination in Multiple Sclerosis. Neuroinflammation 2011. [DOI: 10.1016/b978-0-12-384913-7.00009-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
253 Sachs G. Autoimmune Neuropathies. Clinical Neuroimmunology 2011. [DOI: 10.1007/978-1-60327-860-7_19] [Reference Citation Analysis]
254 Orlikowski D, Sharshar T. Polyradiculonévrite aiguë : le syndrome de Guillain-Barré. EMC - Traité de médecine AKOS 2011;6:1-7. [DOI: 10.1016/s1634-6939(11)52311-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Zhu W, Zhang K, Mix E, Wang X, Adem A, Zhu J. Differential susceptibility to experimental autoimmune neuritis in Lewis rat strains is associated with T-cell immunity to myelin antigens. J Neurosci Res 2011;89:448-56. [DOI: 10.1002/jnr.22541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
256 Yerdelen D, Karataş M. Neurological complications without eclampsia during pregnancy in Turkey: Neurological complications and pregnancy. Journal of Obstetrics and Gynaecology Research 2011;37:202-8. [DOI: 10.1111/j.1447-0756.2010.01337.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Shahrizaila N, Yuki N. Guillain-barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011;2011:829129. [PMID: 21197269 DOI: 10.1155/2011/829129] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 4.4] [Reference Citation Analysis]
258 Lu MO, Zhu J. The role of cytokines in Guillain-Barré syndrome. J Neurol 2011;258:533-48. [PMID: 21104265 DOI: 10.1007/s00415-010-5836-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
259 van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol. 2010;30 Suppl 1:S74-S78. [PMID: 20396937 DOI: 10.1007/s10875-010-9407-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 5.3] [Reference Citation Analysis]
260 Steiner I, Rosenberg G, Wirguin I. Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome? Clin Exp Immunol 2010;162:32-40. [PMID: 20735441 DOI: 10.1111/j.1365-2249.2010.04223.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
261 Awad A, Mathew S, Katirji B. Acute motor axonal neuropathy in association with Sjögren syndrome: Short Reports. Muscle Nerve 2010;42:828-30. [DOI: 10.1002/mus.21830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
262 Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A, Lee SJ, Pavletic SZ, Holler E, Kleiter I. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010;133:2852-2865. [PMID: 20846944 DOI: 10.1093/brain/awq245] [Cited by in Crossref: 150] [Cited by in F6Publishing: 157] [Article Influence: 11.5] [Reference Citation Analysis]
263 Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
264 Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins--a review of the literature. Clin Rev Allergy Immunol 2010;38:201-69. [PMID: 19590986 DOI: 10.1007/s12016-009-8155-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
265 Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M; Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599-612. [PMID: 20600491 DOI: 10.1016/j.vaccine.2010.06.003] [Cited by in Crossref: 388] [Cited by in F6Publishing: 406] [Article Influence: 29.8] [Reference Citation Analysis]
266 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010;:CD002063. [PMID: 20556755 DOI: 10.1002/14651858.CD002063.pub4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
267 Randall DP. Guillain-Barré Syndrome Differential Diagnosis. Disease-a-Month 2010;56:266-78. [DOI: 10.1016/j.disamonth.2010.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
268 Randall DP. Treatment of Guillain-Barré Syndrome. Disease-a-Month 2010;56:279-87. [DOI: 10.1016/j.disamonth.2010.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Bunney EB, Gallagher EJ. Peripheral Nerve Disorders. Rosen's Emergency Medicine – Concepts and Clinical Practice 2010. [DOI: 10.1016/b978-0-323-05472-0.00105-5] [Reference Citation Analysis]
270 Liu GT, Volpe NJ, Galetta SL. Eyelid and facial nerve disorders. Neuro-Ophthalmology 2010. [DOI: 10.1016/b978-1-4160-2311-1.00014-7] [Reference Citation Analysis]
271 Cordova FC, Lim MRC, Criner GJ. Neuromyopathies in the Critically Ill. Critical Care Study Guide 2010. [DOI: 10.1007/978-0-387-77452-7_29] [Reference Citation Analysis]
272 Martín-peña N, Morell Sixto M, Rodríguez de Mingo E. Doctor, tengo hormigueos. SEMERGEN - Medicina de Familia 2010;36:51-55. [DOI: 10.1016/j.semerg.2009.09.002] [Reference Citation Analysis]
273 Matsuzawa Y, Sakakibara R, Shoda T, Kishi M, Ogawa E. Good maternal and fetal outcomes of predominantly sensory Guillain–Barré syndrome in pregnancy after intravenous immunoglobulin. Neurol Sci 2010;31:201-3. [DOI: 10.1007/s10072-009-0188-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
274 Kuitwaard K, de Gelder J, Tio-gillen AP, Hop WCJ, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66:597-603. [DOI: 10.1002/ana.21737] [Cited by in Crossref: 147] [Cited by in F6Publishing: 151] [Article Influence: 10.5] [Reference Citation Analysis]
275 van Doorn PA. What's new in Guillain-Barré syndrome in 2007-2008? J Peripher Nerv Syst 2009;14:72-4. [PMID: 19691528 DOI: 10.1111/j.1529-8027.2009.00215.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
276 Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. Blood Transfus 2009;7:216-34. [PMID: 19657486 DOI: 10.2450/2009.0094-09] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
277 Heiser C, Willmann O, Bran G, Kern R, Hörmann K, Stuck BA. [Open rhinophonia in adults: a rare manifestation of cranial polyneuritis]. HNO 2010;58:155-8. [PMID: 19774355 DOI: 10.1007/s00106-009-1913-4] [Reference Citation Analysis]
278 Ma YM, Liu TK, Wong V. Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong. Pediatr Int 2010;52:13-9. [PMID: 19702649 DOI: 10.1111/j.1442-200X.2009.02951.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
279 Marn Pernat A, Buturović-ponikvar J, Švigelj V, Ponikvar R. Guillain-Barré Syndrome Treated by Membrane Plasma Exchange and/or Immunoadsorption. Therapeutic Apheresis and Dialysis 2009;13:310-3. [DOI: 10.1111/j.1744-9987.2009.00730.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
280 Dhar R. NEUROMUSCULAR RESPIRATORY FAILURE. CONTINUUM: Lifelong Learning in Neurology 2009;15:40-67. [DOI: 10.1212/01.con.0000348809.76308.c0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
281 Sakakibara R, Uchiyama T, Kuwabara S, Mori M, Ito T, Yamamoto T, Awa Y, Yamaguchi C, Yuki N, Vernino S, Kishi M, Shirai K. Prevalence and mechanism of bladder dysfunction in Guillain-Barré Syndrome. Neurourol Urodyn 2009;28:432-7. [DOI: 10.1002/nau.20663] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
282 Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: An update. Journal of Clinical Neuroscience 2009;16:733-41. [DOI: 10.1016/j.jocn.2008.08.033] [Cited by in Crossref: 166] [Cited by in F6Publishing: 177] [Article Influence: 11.9] [Reference Citation Analysis]
283 Stangel M, Hartung H, Gold R, Kieseier B. Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien. Nervenarzt 2009;80:678-687. [DOI: 10.1007/s00115-008-2631-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
284 Buenz EJ. Comment on "Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin". J Clin Neurosci 2009;16:1110; author reply 1111. [PMID: 19467870 DOI: 10.1016/j.jocn.2008.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
285 Rabie M, Nevo Y. Childhood acute and chronic immune-mediated polyradiculoneuropathies. European Journal of Paediatric Neurology 2009;13:209-18. [DOI: 10.1016/j.ejpn.2008.04.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
286 Alshekhlee A, Hussain Z, Sultan B, Katirji B. Immunotherapy for Guillain-Barré syndrome in the US hospitals. J Clin Neuromuscul Dis 2008;10:4-10. [PMID: 18772694 DOI: 10.1097/CND.0b013e318182b5ce] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
287 Amaya Villar R, Garnacho-montero J, Rincón Ferrari M. Patología neuromuscular en cuidados intensivos. Medicina Intensiva 2009;33:123-33. [DOI: 10.1016/s0210-5691(09)70945-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
288 . Individual patients who experienced both Guillain-Barré syndrome and CIDP. Journal of the Peripheral Nervous System 2009;14:66-8. [DOI: 10.1111/j.1529-8027.2009.00208.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
289 Steck AJ, Czaplinski A, Renaud S. Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update. Neurotherapeutics 2008;5:528-34. [PMID: 19019303 DOI: 10.1016/j.nurt.2008.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
290 Crean P, Hicks E. Essentials of Neurology and Neuromuscular Disease. A Practice of Anesthesia for Infants and Children 2009. [DOI: 10.1016/b978-141603134-5.50026-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
291 Mirski MA, Stevens RD, Geocadin RG, Carhuapoma J, Ziai WC, Hanley DF, Nyquist PA, Naval NS, Koenig M. Critical Care Neurology. Atlas of Clinical Neurology 2009. [DOI: 10.1007/978-1-57340-359-7_4] [Reference Citation Analysis]
292 van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939-950. [PMID: 18848313 DOI: 10.1016/s1474-4422(08)70215-1] [Cited by in Crossref: 485] [Cited by in F6Publishing: 400] [Article Influence: 32.3] [Reference Citation Analysis]
293 van Doorn PA, Ruts L, Jacobs BC. Guillain-Barré syndrome – Authors' reply. The Lancet Neurology 2008;7:1083-1085. [DOI: 10.1016/s1474-4422(08)70250-3] [Reference Citation Analysis]
294 Scozzafava J, Jickling G, Jhamandas JH, Jacka MJ. Guillain-Barré syndrome following thoracic spinal cord trauma. Can J Anaesth 2008;55:441-6. [PMID: 18591702 DOI: 10.1007/BF03016311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
295 Rehberg S, Freise H, Young P, Ertmer C, Ellger B, Van Aken H, Westphal M. Das Sepsis-assoziierte Guillain-Barré-Syndrom. Anaesthesist 2009;58:153-5. [DOI: 10.1007/s00101-008-1471-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
296 Kieseier BC, Meyer Zu Hörste G, Lehmann HC, Gold R, Hartung HP. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 2008;21:555-62. [PMID: 18769249 DOI: 10.1097/WCO.0b013e32830efc03] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
297 Lehmann HC, Hartung H, Meyer zu Hörste G, Kieseier BC. Plasma exchange in immune-mediated neuropathies. Current Opinion in Neurology 2008;21:547-54. [DOI: 10.1097/wco.0b013e32830b0f61] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
298 van Doorn PA, Merkies IS. How to assess new drugs for neuropathies: advances in trial design and methodology. Current Opinion in Neurology 2008;21:519-26. [DOI: 10.1097/wco.0b013e32830f1e3b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
299 Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Current Opinion in Neurology 2008;21:540-6. [DOI: 10.1097/wco.0b013e32830b84b7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
300 . Current world literature. Curr Opin Neurol 2008;21:615-24. [PMID: 18769258 DOI: 10.1097/WCO.0b013e32830fb782] [Reference Citation Analysis]
301 Cursiefen S, Mäurer M. Immunglobuline in der Neurologie. Nervenarzt 2008;79:67-76. [DOI: 10.1007/s00115-008-2461-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology 2008;15:893-908. [DOI: 10.1111/j.1468-1331.2008.02246.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 219] [Article Influence: 13.9] [Reference Citation Analysis]
303 Dzieciatkowska M, Liu X, Heikema AP, Houliston RS, van Belkum A, Schweda EK, Gilbert M, Richards JC, Li J. Rapid method for sensitive screening of oligosaccharide epitopes in the lipooligosaccharide from Campylobacter jejuni strains isolated from Guillain-Barré syndrome and Miller Fisher syndrome patients. J Clin Microbiol 2008;46:3429-36. [PMID: 18753342 DOI: 10.1128/JCM.00681-08] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
304 Deng H, Yang X, Jin T, Wu J, Hu L, Chang M, Sun X, Adem A, Winblad B, Zhu J. The role of IL-12 and TNF-α in AIDP and AMAN: IL-12 and TNF-a in GBS. European Journal of Neurology 2008;15:1100-5. [DOI: 10.1111/j.1468-1331.2008.02261.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
305 Hughes R. The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol 2008;255:7-11. [DOI: 10.1007/s00415-008-3003-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
306 Hughes RAC. Treating nerves: a call to arms. Journal of the Peripheral Nervous System 2008;13:105-11. [DOI: 10.1111/j.1529-8027.2008.00166.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
307 Yuki N, Kuwabara S. Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007;12:238-49. [PMID: 18042134 DOI: 10.1111/j.1529-8027.2007.00153.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
308 Unterman A, Shoenfeld Y, Chapman J. Guillain-Barré and Other Immune-Mediated Neuropathies. Diagnostic Criteria in Autoimmune Diseases 2008. [DOI: 10.1007/978-1-60327-285-8_78] [Reference Citation Analysis]
309 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2002;:CD001798. [PMID: 12076424 DOI: 10.1002/14651858.CD001798] [Cited by in Crossref: 84] [Cited by in F6Publishing: 103] [Article Influence: 4.0] [Reference Citation Analysis]